Results 191 to 200 of about 5,863 (219)

Autoimmune Hemolytic Anemia Following MF59-Adjuvanted Influenza Vaccine Administration: A Report of Two Cases

Annals of Pharmacotherapy, 2010
Objective To describe 2 cases of autoimmune hemolytic anemia (AIHA) following the administration of MF59-adjuvanted influenza vaccine. Case Summary: An 83-year-old white woman developed persistent hyperpyrexia, polyarthralgia, and lower limb hypostenia about 2 days after receiving influenza vaccine.
MONTAGNANI S, TUCCORI M, LOMBARDO G, TESTI A, MANTARRO, STEFANIA, RUGGIERO E, BLANDIZZI, CORRADO   +6 more
openaire   +3 more sources

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

Molecular Medicine Today, 1997
Vaccines produced by recombinant DNA technology are safer than 'traditional' vaccines but they are often poorly immunogenic, requiring adjuvants to enhance their immunogenicity. Particulate adjuvants of defined dimensions (< 5 microns) have been shown to be effective in enhancing the immunogenicity of 'weak' antigens in animal models.
D T, O'Hagan, G S, Ott, G, Van Nest
openaire   +2 more sources

MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines

1995
MF59 is a safe, practical, and potent adjuvant for use with human vaccines. The formulation is easily manufactured, may be sterilized by filtration, and is both compatible and efficacious with all antigens tested to date. MF59 has been shown to be a potent stimulator of cellular and humoral responses to subunit antigens in both animal models and ...
G, Ott, G L, Barchfeld, D, Chernoff, R, Radhakrishnan, P, van Hoogevest, G, Van Nest   +5 more
openaire   +2 more sources

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Ca-A Cancer Journal for Clinicians, 2023
Balazs Dome
exaly  

MF59-adjuvanted influenza vaccine cost effective

PharmacoEconomics & Outcomes News, 2020
openaire   +1 more source

Management of glioblastoma: State of the art and future directions

Ca-A Cancer Journal for Clinicians, 2020
Aaron Tan, David M Ashley, Giselle Lopez
exaly  

The Adjuvant MF59: A 10-Year Perspective

2003
Gary Ott, Ramachandran Radhakrishnan, Jia-Hwa Fang, Maninder Hora   +3 more
openaire   +1 more source

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly  

Adjuvant Treatment of Colorectal Cancer

Ca-A Cancer Journal for Clinicians, 2007
Brian M Wolpin
exaly  

MF59 Adjuvant Emulsion

2004
openaire   +1 more source